- Home
- ERAS vs XPOF Comparison
ERAS vs XPOF Comparison
Compare ERAS & XPOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- XPOF
- Stock Information
- Founded
- ERAS 2018
- XPOF 2017
- Country
- ERAS United States
- XPOF United States
- Employees
- ERAS N/A
- XPOF N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- XPOF Services-Misc. Amusement & Recreation
- Sector
- ERAS Health Care
- XPOF Consumer Discretionary
- Exchange
- ERAS Nasdaq
- XPOF Nasdaq
- Market Cap
- ERAS 348.4M
- XPOF 295.1M
- IPO Year
- ERAS 2021
- XPOF 2021
- Fundamental
- Price
- ERAS $1.45
- XPOF $10.04
- Analyst Decision
- ERAS Strong Buy
- XPOF Buy
- Analyst Count
- ERAS 6
- XPOF 9
- Target Price
- ERAS $4.83
- XPOF $13.94
- AVG Volume (30 Days)
- ERAS 1.2M
- XPOF 788.3K
- Earning Date
- ERAS 08-11-2025
- XPOF 07-31-2025
- Dividend Yield
- ERAS N/A
- XPOF N/A
- EPS Growth
- ERAS N/A
- XPOF N/A
- EPS
- ERAS N/A
- XPOF N/A
- Revenue
- ERAS N/A
- XPOF $317,536,000.00
- Revenue This Year
- ERAS N/A
- XPOF $1.62
- Revenue Next Year
- ERAS N/A
- XPOF $6.11
- P/E Ratio
- ERAS N/A
- XPOF N/A
- Revenue Growth
- ERAS N/A
- XPOF N/A
- 52 Week Low
- ERAS $1.01
- XPOF $6.64
- 52 Week High
- ERAS $3.45
- XPOF $18.95
- Technical
- Relative Strength Index (RSI)
- ERAS 52.19
- XPOF 63.94
- Support Level
- ERAS $1.38
- XPOF $8.86
- Resistance Level
- ERAS $1.58
- XPOF $10.14
- Average True Range (ATR)
- ERAS 0.11
- XPOF 0.53
- MACD
- ERAS 0.01
- XPOF 0.28
- Stochastic Oscillator
- ERAS 64.86
- XPOF 93.97
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About XPOF Xponential Fitness Inc.
Xponential Fitness Inc is a curator of boutique fitness brands. Its diversified portfolio of brands includes Club Pilates, a Pilates brand in the United States; CycleBar, an indoor cycling brand in the United States; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix a franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; Stride, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program. Its key revenue source is franchise income.